Pluri (PLUR) Competitors $4.30 -0.01 (-0.23%) Closing price 03:58 PM EasternExtended Trading$4.30 0.00 (-0.12%) As of 06:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PLUR vs. NVCT, NKTX, PEPG, BTMD, CYBN, ONCY, SAVA, FATE, CLYM, and PYXSShould you be buying Pluri stock or one of its competitors? The main competitors of Pluri include Nuvectis Pharma (NVCT), Nkarta (NKTX), PepGen (PEPG), biote (BTMD), Cybin (CYBN), Oncolytics Biotech (ONCY), Cassava Sciences (SAVA), Fate Therapeutics (FATE), Climb Bio (CLYM), and Pyxis Oncology (PYXS). These companies are all part of the "pharmaceutical products" industry. Pluri vs. Its Competitors Nuvectis Pharma Nkarta PepGen biote Cybin Oncolytics Biotech Cassava Sciences Fate Therapeutics Climb Bio Pyxis Oncology Pluri (NASDAQ:PLUR) and Nuvectis Pharma (NASDAQ:NVCT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations. Which has more risk & volatility, PLUR or NVCT? Pluri has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500. Comparatively, Nuvectis Pharma has a beta of -0.29, meaning that its share price is 129% less volatile than the S&P 500. Which has better earnings & valuation, PLUR or NVCT? Nuvectis Pharma has lower revenue, but higher earnings than Pluri. Nuvectis Pharma is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPluri$1.34M26.19-$22.58M-$5.17-0.83Nuvectis PharmaN/AN/A-$19M-$1.17-5.22 Does the media refer more to PLUR or NVCT? In the previous week, Pluri's average media sentiment score of 0.00 equaled Nuvectis Pharma'saverage media sentiment score. Company Overall Sentiment Pluri Neutral Nuvectis Pharma Neutral Is PLUR or NVCT more profitable? Nuvectis Pharma has a net margin of 0.00% compared to Pluri's net margin of -1,701.19%. Nuvectis Pharma's return on equity of -150.81% beat Pluri's return on equity.Company Net Margins Return on Equity Return on Assets Pluri-1,701.19% -4,191.91% -88.27% Nuvectis Pharma N/A -150.81%-94.84% Do insiders & institutionals believe in PLUR or NVCT? 16.6% of Pluri shares are owned by institutional investors. Comparatively, 96.8% of Nuvectis Pharma shares are owned by institutional investors. 25.9% of Pluri shares are owned by company insiders. Comparatively, 30.5% of Nuvectis Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts recommend PLUR or NVCT? Pluri presently has a consensus price target of $12.00, indicating a potential upside of 179.07%. Nuvectis Pharma has a consensus price target of $15.33, indicating a potential upside of 150.95%. Given Pluri's higher possible upside, equities research analysts plainly believe Pluri is more favorable than Nuvectis Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pluri 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Nuvectis Pharma 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryNuvectis Pharma beats Pluri on 8 of the 13 factors compared between the two stocks. Get Pluri News Delivered to You Automatically Sign up to receive the latest news and ratings for PLUR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PLUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PLUR vs. The Competition Export to ExcelMetricPluriMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$35.15M$3.35B$6.12B$10.65BDividend YieldN/A2.29%5.69%4.74%P/E Ratio-0.8321.4185.6126.85Price / Sales26.19466.25612.81135.13Price / CashN/A47.6737.7861.77Price / Book-39.0910.0613.256.70Net Income-$22.58M-$52.22M$3.30B$276.44M7 Day Performance-4.02%5.84%4.70%3.13%1 Month Performance-15.67%12.05%8.43%10.21%1 Year Performance-15.69%26.13%88.01%40.35% Pluri Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PLURPluri1.7409 of 5 stars$4.30-0.2%$12.00+179.1%-17.0%$35.15M$1.34M-0.83150Positive NewsNVCTNuvectis Pharma2.6322 of 5 stars$5.95+0.5%$15.33+157.7%-0.8%$151.34MN/A-5.088NKTXNkarta2.3221 of 5 stars$2.10+1.2%$13.60+549.2%-45.2%$148.81MN/A-1.42140PEPGPepGen3.7733 of 5 stars$4.52-2.6%$8.40+85.9%-46.7%$148.42MN/A-1.5330BTMDbiote2.3278 of 5 stars$2.99flat$6.00+100.7%-43.3%$147.82M$199.07M3.32194CYBNCybinN/A$5.86-2.3%$85.00+1,351.8%N/A$147.22MN/A-1.3350ONCYOncolytics Biotech1.5371 of 5 stars$1.40-0.7%$5.00+257.1%+23.6%$140.00MN/A-5.1730SAVACassava Sciences3.021 of 5 stars$2.88-8.4%$2.00-30.4%-86.8%$138.89MN/A-1.1330News CoverageFATEFate Therapeutics3.9443 of 5 stars$1.22+21.5%$3.30+171.6%-56.2%$137.82M$13.63M-0.82550High Trading VolumeCLYMClimb Bio4.0591 of 5 stars$2.00+0.5%$9.25+362.5%N/A$135.52MN/A-2.869Analyst UpgradeShort Interest ↓PYXSPyxis Oncology1.8265 of 5 stars$2.19-0.7%$7.75+254.7%-30.2%$135.51M$2.82M-1.3760Positive News Related Companies and Tools Related Companies Nuvectis Pharma Competitors Nkarta Competitors PepGen Competitors biote Competitors Cybin Competitors Oncolytics Biotech Competitors Cassava Sciences Competitors Fate Therapeutics Competitors Climb Bio Competitors Pyxis Oncology Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PLUR) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pluri Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pluri With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
